ArticleCost effectiveness and resource allocation : C/E2021

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.

Mafalda Ramos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.